ETL, a Novel Seven-transmembrane Receptor That is Developmentally Regulated in the Heart. ETL is a Member of the Secretin Family and Belongs to the Epidermal Growth Factor-seven-transmembrane Subfamily
Overview
Authors
Affiliations
Using differential display of rat fetal and postnatal cardiomyocytes, we have identified a novel seven-transmembrane receptor, ETL. The cDNA-predicted amino acid sequence of ETL indicated that it encodes a 738-aa protein composed of a large extracellular domain with epidermal growth factor (EGF)-like repeats, a seven-transmembrane domain, and a short cytoplasmic tail. ETL belongs to the secretin family of G-protein-coupled peptide hormone receptors and the EGF-TM7 subfamily of receptors. The latter are characterized by a variable number of extracellular EGF and cell surface domains and conserved seven transmembrane-spanning regions. ETL mRNA expression is up-regulated in the adult rat and human heart. In situ hybridization analyses revealed expression in rat cardiomyocytes and abundant expression in vascular and bronchiolar smooth muscle cells. In COS-7 cells transfected with Myc-tagged rat ETL, rat ETL exists as a stable dimer and undergoes endoproteolytic cleavage of the extracellular domain. The proteolytic activity can be abolished by a specific mutation, T455A, in this domain. In transfected mammalian cells, ETL is associated with cell membranes and is also observed in cytoplasmic vesicles. ETL is the first seven-transmembrane receptor containing EGF-like repeats that is developmentally regulated in the heart.
Sheldon H, Zhang W, Bridges E, Ang K, Lin S, Masiero M J Extracell Biol. 2024; 1(8):e52.
PMID: 38939053 PMC: 11080856. DOI: 10.1002/jex2.52.
Geng G, Zhang L, Yu Y, Guo X, Li Q, Ming M Curr Mol Med. 2024; 25(1):45-55.
PMID: 38178660 DOI: 10.2174/0115665240254765231117122210.
Adhesion G protein-coupled receptor gluing action guides tissue development and disease.
Sreepada A, Tiwari M, Pal K J Mol Med (Berl). 2022; 100(10):1355-1372.
PMID: 35969283 DOI: 10.1007/s00109-022-02240-0.
ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung K Neurooncol Adv. 2021; 3(1):vdab132.
PMID: 34704036 PMC: 8541707. DOI: 10.1093/noajnl/vdab132.
ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype.
Sheldon H, Alexander J, Bridges E, Moreira L, Reilly S, Ang K Int J Mol Sci. 2021; 22(20).
PMID: 34681953 PMC: 8539764. DOI: 10.3390/ijms222011293.